Oliclinomel N7-1000e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Oliclinomel N7-1000e is used as part of parenteral nutrition regimens to address amino‑acid deficiencies.

• Critical illness: helps maintain nitrogen balance and supports protein synthesis.
• Post‑operative recovery: contributes to wound healing and tissue repair.
• Long‑term home parenteral nutrition: provides essential amino acids for patients unable to meet needs orally.
• Severe malnutrition: assists in restoring lean body mass.
• Metabolic stress states: aids in stabilising metabolic parameters.

• The formulation supplies a balanced mixture of essential and non‑essential amino acids that are directly absorbed into the bloodstream after intravenous infusion. These amino acids serve as substrates for protein synthesis, support gluconeogenesis, and help regulate nitrogen balance, thereby contributing to overall metabolic stability in patients receiving parenteral nutrition.

Adverse reactions are generally related to the intravenous route and the amino‑acid composition.

Common Side Effects

• Mild infusion‑related erythema
• Transient increase in serum ammonia
• Slight elevation of liver enzymes
• Pruritus at the infusion site
• Nausea or mild gastrointestinal discomfort
• Headache

Serious or Rare Side Effects

• Anaphylactic or severe hypersensitivity reaction
• Acute hemolysis
• Severe electrolyte disturbances
• Thromboembolic events linked to catheter use
• Sepsis related to infusion line infection
• Persistent hypotension during infusion

When using Oliclinomel N7-1000e, clinicians should observe standard parenteral nutrition safety measures.

• Patient assessment: evaluate renal and hepatic function before initiation.
• Infusion rate: administer according to recommended speed to avoid metabolic overload.
• Compatibility: verify compatibility with other IV solutions and medications.
• Monitoring: regularly check electrolytes, blood gases, and nitrogen balance.
• Contraindications: avoid in patients with known hypersensitivity to any amino‑acid component.
• Store at ambient temperature: keep in original packaging, protect from light and moisture.

Oliclinomel N7-1000e may interact with other intravenous therapies and medications that affect amino‑acid metabolism.

Major Interactions (Avoid)

• High‑dose corticosteroids: may increase protein catabolism.
• Certain anticonvulsants (e.g., phenobarbital): can alter amino‑acid plasma levels.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may exacerbate electrolyte shifts.
• Insulin therapy: requires careful glucose monitoring due to gluconeogenic substrates.
• Parenteral lipid emulsions: adjust amino‑acid dosing to maintain nitrogen balance.
• Renal replacement therapies: may remove amino acids, affecting dosing.
• Vitamin B6 supplementation: high doses can modify amino‑acid metabolism.